New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out
Loading...
Shape
Cara Therapeutics, Inc.
CARA
Shape
US Flag

NASDAQ

Unprofitable

EPS improving

Unprofitable

EPS improving

14M

Biotechnology

Next Earning date - 11 Nov 2024

14M

Biotechnology

Next Earning date - 11 Nov 2024

0.25USD
Shape-0.00 ( -1.22%)
favorite-chart

Relative Strenght

6
favorite-chart

Volume Buzz

-11%
favorite-chart

Earning Acce

Yes
favorite-chart

Dist 52w H.

85%

Quote Panel

Shape
Updated October 12, 2024
1W -5.86 % 1M -4.53 % 3M -25.19 % 1Y -82.35 %

Key Metrics

Shape
  • Market Cap

    13.74M


  • Shares Outstanding

    54.85M


  • Share in Float

    45.76M


  • Dividende

    0


  • Earning Date

    11 Nov 2024


  • Price Target

    0.2506


  • Average Volume

    402353


  • Beta

    0.699


  • Range

    0.24-1.65


  • Industry

    Biotechnology


  • Website

    https://www.caratherapeutics.com


  • Sector

    Healthcare


Fundamentals

Shape

N/A

P/E Ratio

1.25x

P/S Ratio

1.18x

P/B Ratio

3.4

Debt/Equity

-1010.2%

Net Margin

$-2.0

EPS

How CARA compares to sector?

P/E Ratio

Relative Strength

Shape

CARA

Sector

loading...

Top 5 RS in Group

Symbol

Company

RS

5-Day Perf.

Forecast

Shape

$6M

Shape548%

2025-Revenue

$0.59

Shape-59%

2025-EPS

$5M

Shape68%

2025-EBITDA

Analyst rating

No Data Available

Last analyst upgrade/downgrade

H.C. Wainwright

downgrade

Previous: Not converted

2024-06-13

Now: Neutral

Needham

downgrade

Previous: Buy

2024-06-13

Now: Hold

Canaccord Genuity

downgrade

Previous: Underperform

2024-06-13

Now: Negative

Piper Sandler

downgrade

Previous: Overweight

2023-11-14

Now: Neutral

Earnings GrowthShape

status-upYoY

Current

Estimates

Q3.22

arrow
arrow

N/A

-0.43
vs -0.02

Q4.22

arrow
arrow

N/A

-0.56
vs -0.63

Q1.23

arrow
arrow

N/A

-0.49
vs -0.52

Q2.23

arrow
arrow

N/A

-0.58
vs -0.08

Q3.23

arrow
arrow

N/A

-0.52
vs -0.43

Q4.23

arrow
arrow

N/A

-0.59
vs -0.56

Q1.24

arrow
arrow

N/A

-0.56
vs -0.49

Q2.24

arrow
arrow

N/A

-0.37
vs -0.58

Q3.24

arrow
arrow

N/A

-0.24
vs -0.52

Q4.24

arrow
arrow

N/A

-0.20
vs -0.59

Sales GrowthShape

status-upYoY

Current

Estimates

Q3.22

arrow
arrow

-47%

10.8M  vs 20.3M

Q4.22

arrow
arrow

+297%

3.3M  vs 821K

Q1.23

arrow
arrow

+29%

6.2M  vs 4.8M

Q2.23

arrow
arrow

-70%

6.9M  vs 23M

Q3.23

arrow
arrow

-55%

4.9M  vs 10.8M

Q4.23

arrow
arrow

-8%

3M  vs 3.3M

Q1.24

arrow
arrow

-65%

2.1M  vs 6.2M

Q2.24

arrow
arrow

-86%

991K  vs 6.9M

Q3.24

arrow
arrow

-59%

2M  vs 4.9M

Q4.24

arrow
arrow

-44%

1.7M  vs 3M

Return on EquityShape

status-upQoQ

Q3.22

arrow
arrow

-12%

-0.12
vs -0.02

Q4.22

arrow
arrow

-18%

-0.18
vs -0.12

Q1.23

arrow
arrow

-19%

-0.19
vs -0.18

Q2.23

arrow
arrow

-29%

-0.29
vs -0.19

Q3.23

arrow
arrow

-33%

-0.33
vs -0.29

Q4.23

arrow
arrow

-57%

-0.57
vs -0.33

Q1.24

arrow
arrow

-103%

-1.03
vs -0.57

Q2.24

arrow
arrow

-173%

-1.73
vs -1.03

Institutionnal OwnershipShape

status-upQoQ

Q3.22

arrow
arrow

163

163
vs 180

-9%

Q4.22

arrow
arrow

168

168
vs 163

3%

Q1.23

arrow
arrow

167

167
vs 168

-1%

Q2.23

arrow
arrow

140

140
vs 167

-16%

Q3.23

arrow
arrow

126

126
vs 140

-10%

Q4.23

arrow
arrow

113

113
vs 126

-10%

Q1.24

arrow
arrow

100

100
vs 113

-11%

Q2.24

arrow
arrow

80

80
vs 100

-20%

Earnings Growth

Latest News